179 results match your criteria: "Karolinska Comprehensive Cancer Center[Affiliation]"
J Neurol Neurosurg Psychiatry
January 2024
Department of Medical Sciences, Uppsala University, Uppsala, Sweden
Background: A growing evidence base supports the use of autologous haematopoietic stem cell transplantation (aHSCT) for treatment of relapsing-remitting multiple sclerosis (RRMS), but it has not yet been integrated into most national clinical guidelines. The objective of this study was to assess efficacy and safety when aHSCT is implemented in routine healthcare.
Methods: We assessed 231 patients and the final analysis included 174 RRMS patients who were treated with aHSCT in Sweden before 1 January 2020.
Oncologist
January 2024
Oncology/Pathology Department, Karolinska Institute, Stockholm, Sweden.
Background: Breast surgery in cases of de novo metastatic breast cancer (MBC) is associated with improved outcomes in retrospective studies, although the results of randomized controlled trials (RCTs) are conflicting. We aimed to investigate whether surgery in this context prolongs patient survival.
Methods: We performed a systematic review of the literature to identify RCTs comparing surgery of primary breast cancer to no surgery in patients with de novo MBC.
Bone Marrow Transplant
December 2023
Ospedale San Raffaele s.r.l., Haematology and BMT, Milan, Italy.
The COVID-19 pandemic has had a significant impact on medical practices, including the delivery of allogeneic hematopoietic cell transplantation (HCT). In response, transplant centers have made changes to their procedures, including an increased use of cryopreservation for allogeneic haematopoietic progenitor cell (HPC) grafts. The use of cryopreserved grafts for allogeneic HCT has been reviewed and analysed in terms of potential benefits and drawbacks based on existing data on impact on cell subsets, hematological recovery, and clinical outcomes of approximately 2000 patients from different studies.
View Article and Find Full Text PDFESMO Open
October 2023
Centre for Dermatooncology, Eberhard Karls University of Tübingen, Tübingen; Cluster of Excellence IFIT (EXC2180), Tübingen, Germany.
Sci Adv
September 2023
Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
Open Forum Infect Dis
August 2023
Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Signal Transduct Target Ther
August 2023
Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute, 14157, Stockholm, Sweden.
EJNMMI Res
August 2023
Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Background: In vivo monitoring of cell biodistribution using positron emission tomography (PET) provides a quantitative non-invasive method to further optimize cell therapies and related new developments in the field. Our group has earlier optimized and evaluated the in vitro properties of two radiotracers,[Zr]Zr-(oxinate) and [Zr]Zr-DFO-NCS, for the radiolabelling of different cell types. Here, we performed a microPET study to assess the in vivo biodistribution of cells in rats using these two radiotracers.
View Article and Find Full Text PDFCancer Nurs
August 2024
Author Affiliations: School of Nursing, The Hong Kong Polytechnic University (Drs Molassiotis and Abu-Odah), Hong Kong SAR; Health and Social Care Research Centre, University of Derby (Dr Molassiotis), United Kingdom; School of Health Sciences, University of Manchester (Dr Yorke), United Kingdom; The Christie NHS Foundation Trust (Dr Yorke); School of Nursing, Midwifery & Social Work, University of Queensland (Dr McCarthy), Brisbane, Australia; Division of Neurobiology, Care Sciences & Society, Karolinska Institute, Karolinska Comprehensive Cancer Center, Karolinska University Hospital (Dr Wengstrom), Stockholm, Sweden; and School of Health Sciences, University of Surrey (Dr Gibson); and Centre for Outcomes and Experience Research in Children's Health, Illness and Disability, Great Ormond Street Hospital for Children NHS Foundation Trust (Dr Gibson), London, United Kingdom.
Background: Research led by nurses has evolved rapidly over the last 2 decades globally. Assessing the work that has been conducted so far can help the specialty to strategically shape future directions of nurse-led cancer research.
Objective: The aim of this study was to provide a comprehensive, up-to-date synthesis of all nurse-led cancer research published articles over 20 years.
JAMA Oncol
September 2023
Department of Oncology and Pathology, Karolinska Institutet and University Hospital, Stockholm, Sweden.
Leukemia
September 2023
Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden.
Isocitrate dehydrogenase (IDH) mutations are found in 20% of acute myeloid leukemia (AML) patients. However, only 30-40% of the patients respond to IDH inhibitors (IDHi). We aimed to identify a molecular vulnerability to tailor novel therapies for AML patients with IDH mutations.
View Article and Find Full Text PDFSci Adv
July 2023
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chimeric antigen receptor (CAR) engineering of natural killer (NK) cells is promising, with early-phase clinical studies showing encouraging responses. However, the transcriptional signatures that control the fate of CAR-NK cells after infusion and factors that influence tumor control remain poorly understood. We performed single-cell RNA sequencing and mass cytometry to study the heterogeneity of CAR-NK cells and their in vivo evolution after adoptive transfer, from the phase of tumor control to relapse.
View Article and Find Full Text PDFJNCI Cancer Spectr
July 2023
Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Current evidence on de novo metastatic breast cancer is based on data from women. This Swedish population-based cohort study compared the incidence over time and prognosis of de novo metastatic breast cancer between sexes using data from the Swedish National Quality Register for Breast Cancer. Joinpoint regression analysis was used to compare incidence trends in all stages (104 733 women, 648 men) and multivariate Cox regression analysis to investigate potential sex disparities in de novo metastatic breast cancer prognosis (6005 women, 41 men).
View Article and Find Full Text PDFLeukemia
September 2023
Institute of Haematology, Faculty of Medicine and Surgery, "Sacro Cuore" Catholic University, Rome, Italy.
EBioMedicine
August 2023
Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden. Electronic address:
Background: Immunocompromised patients have varying responses to SARS-CoV-2 mRNA vaccination. However, there is limited information available from prospective clinical trial cohorts with respect to long-term immunogenicity-related responses in these patient groups following three or four vaccine doses, and in applicable cases infection.
Methods: In a real-world setting, we assessed the long-term immunogenicity-related responses in patients with primary and secondary immunodeficiencies from the prospective open-label clinical trial COVAXID.
J Infect Dis
January 2024
Hematology Department, Hospital de la Princesa, Madrid, Spain.
Background: Human metapneumovirus (hMPV) epidemiology, clinical characteristics and risk factors for poor outcome after allogeneic stem cell transplantation (allo-HCT) remain a poorly investigated area.
Methods: This retrospective multicenter cohort study examined the epidemiology, clinical characteristics, and risk factors for poor outcomes associated with human metapneumovirus (hMPV) infections in recipients of allo-HCT.
Results: We included 428 allo-HCT recipients who developed 438 hMPV infection episodes between January 2012 and January 2019.
Sci Transl Med
July 2023
Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden.
Suboptimal immunity to SARS-CoV-2 mRNA vaccination has frequently been observed in individuals with various immunodeficiencies. Given the increased antibody evasion properties of emerging SARS-CoV-2 subvariants, it is necessary to assess whether other components of adaptive immunity generate resilient and protective responses against infection. We assessed T cell responses in 279 individuals, covering five different immunodeficiencies and healthy controls, before and after booster mRNA vaccination, as well as after Omicron infection in a subset of patients.
View Article and Find Full Text PDFBreast Cancer Res Treat
September 2023
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Introduction: In light of the clinically meaningful results of the PI3K inhibitors in PIK3CA-mutated metastatic breast cancer (BC) patients, the reliable identification of PIK3CA mutations is of outmost importance. However, lack of evidence on the optimal site and timing of assessment, presence of temporal heterogeneity and analytical factors pose several challenges in clinical routine. We aimed to study the discordance rates of PIK3CA mutational status between primary and matched metastatic tumors.
View Article and Find Full Text PDFBreast
August 2023
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Breast Cancer Center, Department of Breast, Endocrine Tumours and Sarcoma, Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden.
Int J Environ Res Public Health
May 2023
Department of Nursing, Umeå University, SE-90187 Umeå, Sweden.
It is estimated that 40% of the cancer cases in Europe could be prevented if people had better information and tools to make healthier choices and thereby reduce some of the most important cancer risk factors. The aim of this study is to gain knowledge and understanding about cancer prevention literacy among people with intellectual disabilities, immigrants, young people and young cancer survivors. In this qualitative study, we conducted six online focus-group interviews, including forty participants, to explore the cancer prevention literacy of four population subgroups and determine how cancer prevention recommendations according to the European Code Against Cancer (ECAC) were perceived.
View Article and Find Full Text PDFEJNMMI Res
May 2023
Medical Radiation Physics and Nuclear Medicine, Functional Unit of Nuclear Medicine, Karolinska University Hospital, Huddinge, Sweden.
Bone Marrow Transplant
August 2023
Hematology Department, Hospital de la Princesa, Madrid, Spain.
We previously analyzed trends in incidence and factors associated with lethal complications in ALL/AML/CML patients (causes of deaths; COD-1 study). The objective of this study was the analysis of incidence and specific causes of death after HCT, with focus on infectious deaths in two time periods, 1980-2001 (cohort-1) and 2002-2015 (cohort-2). All patients with HCT for lymphoma, plasma cell disorders, chronic leukemia (except CML), myelodysplastic/myeloproliferative disorders, registered in the EBMT-ProMISe-database were included (n = 232,618) (COD-2 study).
View Article and Find Full Text PDFEur J Cancer
July 2023
"Sandro Pitigliani" Department of Medical Oncology, Hospital of Prato, Prato, Italy. Electronic address:
Aims: Improvement in the care of patients with metastatic breast cancer (MBC) can only occur if the adequate quality of care is implemented and verified, including access to multidisciplinary, specialised care given in accordance with high-quality guidelines. To this purpose, European Society of Breast Cancer Specialists and the Advanced Breast Cancer Global Alliance joined efforts to develop the first set of quality indicators (QI) specifically for MBC that should be routinely measured and evaluated to ensure that breast cancer centres meet the required standards.
Methods: A working group of multidisciplinary European experts in breast cancer met to discuss each identified QI, reporting the definition, the minimum and target standard for breast cancer centres to achieve, and the motivation for selection.
Pharmaceutics
April 2023
Department of Oncology-Pathology, BioClinicum, Karolinska University Hospital Solna, Karolinska Institutet, 171 64 Stockholm, Sweden.
The ROR1 receptor tyrosine kinase is expressed in embryonic tissues but is absent in normal adult tissues. ROR1 is of importance in oncogenesis and is overexpressed in several cancers, such as NSCLC. In this study, we evaluated ROR1 expression in NSCLC patients (N = 287) and the cytotoxic effects of a small molecule ROR1 inhibitor (KAN0441571C) in NSCLC cell lines.
View Article and Find Full Text PDF